Skip to main content
    T

    TriSalus Life Sciences Inc. (TLSI)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.27
    -0.16 (-6.58%)

    Market Cap: $149.93M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    TriSalus Life Sciences Inc. (TLSI) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, TriSalus Life Sciences reported EPS of -$0.15, below the -$0.14 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    33%(4/12)
    Avg Surprise
    -35.64%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.06
    Range-$0.11 - -$0.04
    7 analysts
    Revenue Consensus
    $13.81M
    Range$12.64M - $14.80M
    7 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.11
    Range-$0.15 - -$0.09
    3 analysts
    EPS Estimate DriftChange to current
    90d ago-$0.11-7.9%
    60d ago-$0.11-6.2%
    30d ago-$0.10-9.7%
    7d ago-$0.10-9.7%
    Current-$0.11
    Revenue Consensus
    $14.49M
    Range$10.10M - $17.04M
    4 analysts

    Next Report

    TLSI's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    TLSI Earnings Call

    The latest TLSI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 12 quarters below that had an estimate, TLSI beat 4 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $12.88M, up 11.3% from $11.57M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.15-$0.14-$0.15 - -$0.09-7.14%MissN/A50 up, 0 downNov 10, 2026$12.88M
    Jun 30, 2026-$0.16-$0.15-$0.19 - -$0.14-6.67%MissN/A40 up, 1 downAug 6, 2026$11.41M
    Mar 31, 2026$0.03-$0.16-$0.16 - -$0.16+118.38%BeatN/A10 up, 1 downMay 12, 2026$8.90M
    Dec 31, 2025-$0.05-$0.13-$0.13 - -$0.13+61.54%BeatN/A10 up, 1 downMar 5, 2026$13.21M
    Sep 30, 2025-$0.87-$0.16-$0.19 - -$0.14-443.75%MissN/A21 up, 2 downNov 13, 2025$11.57M
    Jun 30, 2025-$0.23-$0.22-$0.24 - -$0.19-4.55%MissN/A31 up, 2 downAug 12, 2025$11.21M
    Mar 31, 2025-$0.33-$0.20-$0.26 - -$0.09-65.00%MissN/A31 up, 0 downMay 15, 2025$9.17M
    Dec 31, 2024-$0.40-$0.35-$0.35 - -$0.35-14.29%MissN/A10 up, 0 downMar 27, 2025$8.26M
    Sep 30, 2024-$0.40-$0.36-$0.37 - -$0.36-11.11%MissN/A20 up, 0 downNov 14, 2024$7.35M
    Jun 30, 2024-$0.21-$0.46N/A+54.35%BeatN/A30 up, 0 downAug 14, 2024$7.36M
    Mar 31, 2024-$0.60-$0.72-$0.72 - -$0.58+16.67%BeatN/A20 up, 0 downMay 15, 2024$6.46M
    Dec 31, 2023-$1.56-$0.69-$0.69 - -$0.69-126.09%MissN/A10 up, 0 downMar 12, 2024$5.72M
    Sep 30, 2023-$0.13N/AN/AN/AN/A-762.0%N/AN/ANov 14, 2023$5.19M
    Jun 30, 2023-$0.12N/AN/AN/AN/A-254.1%N/AN/AAug 30, 2023$4.61M
    Mar 31, 2023-$0.05N/AN/AN/AN/A-160.7%N/AN/AJun 29, 2023$2.98M
    Dec 31, 2022-$0.01N/AN/AN/AN/A-111.1%N/AN/AMar 30, 2023$8.47M
    Sep 30, 2022$0.02N/AN/AN/AN/A-66.7%N/AN/ANov 10, 2022$3.92M
    Jun 30, 2022$0.08N/AN/AN/AN/A+700.0%N/AN/AAug 10, 2022N/A
    Mar 31, 2022$0.09N/AN/AN/AN/AN/AN/AN/AMay 11, 2022N/A
    Dec 31, 2021$0.09N/AN/AN/AN/AN/AN/AN/AMar 2, 2022$2.57M
    Sep 30, 2021$0.06N/AN/AN/AN/AN/AN/AN/ADec 13, 2021N/A
    Jun 30, 2021$0.01N/AN/AN/AN/AN/AN/AN/AAug 16, 2021N/A
    Mar 31, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AJun 28, 2021N/A
    Last 23 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.48, after -$1.61 the year before. It was $0.15 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.48N/A
    Dec 31, 2024-$1.61N/A
    Dec 31, 2023-$1.87-1139.1%
    Dec 31, 2022$0.18N/A
    Dec 31, 2021$0.15N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,8099
    2026Q1Mar 31, 20264,8038
    2025Q4Dec 31, 20255,2188
    2025Q3Sep 30, 20255,22110
    2025Q2Jun 30, 20254,9297
    2025Q1Mar 31, 20255,70111
    2024Q3Sep 30, 20246,2558
    2024Q2Jun 30, 20244,2248

    2026Q3 Earnings Call

    Opening remarks

    Unknown Attendee Company Representative Good morning, and thank you for participating in today's call. Joining me from TriSalus are Mary Szela, President and Chief Executive Officer; David Patience, Chief Financial Officer; and Dr. Richard Marshall, Chief Medical Officer. Earlier today, TriSalus issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of the press release is available on the Investor Relations section of the company's website. Before we begin, I'd like to remind you that management will make remarks during this call that include forward-looking statements within the meaning of federal securities laws and that these are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our Forms 10-Q and 10-K on file with the SEC and available on EDGAR, as well as our other periodic filings. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 10, 2026. TriSalus disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I will turn the call over to Mary.

    Mary Szela President and Chief Executive Officer Good morning, and thank you all for joining us. The third quarter marked an important period of growth and advancement for TriSalus. We drove increasing revenue, both year-over-year and quarter-over-quarter, as our commercial expansion continued and account utilization improved. In addition, in September, we received FDA clearance for TriNav Advance, enabling us to expand our portfolio looking forward. TriNav Advance extends our pressure-enabled drug delivery approach, called PEDD, to small distal vessels through the microcatheter of the physician's choice. These are vessels that TriNav technology could not previously fully address. With TriNav Advance, we now can address the full range of vessels encountered in liver embolization procedures. That means interventional radiologists can keep their preferred workflow while patients still benefit from PEDD. We are now preparing for a limited market release of TriNav Advance to gather early clinical and customer feedback before a broader launch. Milestones like this matter because of the problem we set out to solve. Catheter-based oncology drug delivery has changed very little in decades, even as therapies themselves have advanced dramatically.

    Frequently Asked Questions About TLSI

    Did TLSI beat earnings estimates last quarter?

    No. TriSalus Life Sciences reported EPS of -$0.15 for the quarter ended Sep 30, 2026, below the -$0.14 estimate by 7.14%.

    What EPS do analysts expect from TLSI next quarter?

    The consensus EPS estimate for TriSalus Life Sciences for the quarter ending Dec 31, 2026 is -$0.06 from 7 analysts, with estimates from -$0.11 to -$0.04.

    How often does TLSI beat earnings estimates?

    TriSalus Life Sciences beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -45.18%.